Revlimid maintenance use boosts survival, study shows

Celgene's cancer drug Revlimid significantly extended the lives of patients with multiple myeloma who took the drug as a maintenance therapy following a stem cell transplant. But worries about secondary malignancies spooked investors, sending Celgene shares down. Report | Article

Suggested Articles

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.

A patent decision in Delaware clears the way for multiple generic companies to launch their Tecfidera copycats—and target its $3.3B in U.S. sales.

Sanofi and GlaxoSmithKline signed a deal with the EU to supply up to 300 million doses of their recombinant protein-based COVID-19 vaccine.